Breaking Finance News

A statement released earlier today by Mizuho Securities about Mallinckrodt (NYSE:MNK) bumps the target price to $91.00

Mallinckrodt (NYSE:MNK) had its target price upped to $91 by Mizuho Securities in an issued report issued 8/03/2016. The latest target price suggests a potential upside of 0.18% from the company’s previous stock close price.

Previously on 7/21/2016, Mizuho Securities reported on Mallinckrodt(NYSE:MNK) bumped the target price from $80.00 to $83.00. At the time, this suggested an upside of 0.23%.

Showing a price of $76.91, Mallinckrodt (NYSE:MNK) traded 0.93% lower on the day. The last stock close is up 15.54% from the two hundred day moving average, compared with the S&P 500 Index which has fallen -0.01% over the same time. The company has logged a 50-day average of $76.09 and two hundred day average of $65.27. 786,098 shares of the stock traded hands, down from ann avg. volume of 1,665,100

See Graphic Below:

Mallinckrodt (NYSE:MNK)

With a total market value of $0.0, Mallinckrodt has a one-year low of $50.90 and a one-year high of $86.06 with a PE ratio of 14.

In addition to Mizuho Securities reporting it’s stock price target, a total of 15 analysts have reported on MNK. The consensus target price is $88.67 with six analysts rating the company a strong buy, seven analysts rating the stock a buy, two firms rating the stock a hold, 0 rating the company to underperform, and finally 0 brokeragesrating the stock as sell.

General Information About Mallinckrodt (NYSE:MNK)

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging. Its Specialty Brands segment produces and markets branded pharmaceutical and biopharmaceutical products for autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies, and central nervous system drugs. Its Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic controlled substances, and acetaminophen and other active ingredients. Its Nuclear Imaging segment manufactures and markets radiopharmaceuticals (nuclear medicine).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.